Delivery Order SPE2DB22D3301-SPE2DB25FY4KH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,418.56 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on October 15, 2025, with completion scheduled for October 16, 2025. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Multaq 400 mg tablets (60-count packages) valued at $11,622.61. This competitively awarded, firm fixed-price delivery order is set to be completed by October 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $3,697.14 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Multaq 400 mg tablets (60-count units). The contract, which is a non-set-aside competitive award, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. Performance will take place at AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,549.80 on July 29, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency Medical Supply Chain awarded a $57,770.08 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Multaq 400 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, with performance based in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran...
- The Defense Logistics Agency awarded a $5,463.61 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on June 24, 2025, with completion scheduled for June 25, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, indicating competitive award to the qualified vendor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $11,497.10 firm fixed price delivery order by the Defense Department's Medical Supply Chain on September 12, 2025, for 60 tablets of Multaq 400mg. The award was made competitively with no set-aside designation and has an ultimate completion date of October 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a delivery order valued at $39,860.86 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 27, 2025, with completion targeted for August 28, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order executed under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be performed at the contractor's location in...
- The Defense Logistics Agency awarded a $48,680.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Multaq 400 mg tablets (60-count units). This non-set-aside contract represents a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The delivery order specifies a completion date of...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,422.22 by the Defense Logistics Agency on July 14, 2025, for the supply of Multaq 400 mg tablets (60-count units). The contract is classified as a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and carries no set-aside designation, indicating it was competitively awarded. This delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY4KHDelivery Order
The Defense Logistics Agency awarded a $4,183.38 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on May 6, 2025, with completion targeted for May 7, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving defense and civilian healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal contract awards demonstrates capability in delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Multaq is an antiarrhythmic medication used in the treatment of atrial fibrillation, reflecting the company's role in supplying specialized pharmaceutical products to support military personnel and veteran healthcare needs through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 5/6/25 |